The CLDND2 (Claudin Domain Containing 2) antibody is a tool used to detect the CLDND2 protein, a member of the claudin-like transmembrane protein family. Although not a canonical claudin, CLDND2 shares structural homology with claudins, particularly in its conserved Claudin_ES domain, and is implicated in cell-cell adhesion and barrier formation. This antibody is primarily employed in research to investigate CLDND2's expression and localization in tissues, often via techniques like immunohistochemistry, Western blotting, or immunofluorescence.
CLDND2 has drawn attention for its potential roles in development and disease. Studies suggest its involvement in neurodevelopment, renal tubule formation, and epithelial polarity regulation. Notably, aberrant CLDND2 expression has been observed in cancers, including hepatocellular carcinoma and breast cancer, where it may influence tumor progression or metastasis. The antibody helps clarify its mechanistic contributions, such as interactions with tight junction proteins or signaling pathways like Wnt/β-catenin.
Commercial CLDND2 antibodies are typically raised in rabbits or mice using peptide antigens from human CLDND2 sequences. Researchers must validate specificity due to homology with other claudin proteins. Current challenges include understanding its dual roles in physiological homeostasis and pathological contexts, particularly its tissue-specific functions. Ongoing studies aim to explore its utility as a diagnostic biomarker or therapeutic target in cancer and developmental disorders.